T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Angyal, Adrienn; Longet, Stephanie; Moore, Shona C.; Payne, Rebecca P.; Harding, Adam; Tipton, Tom; Rongkard, Patpong; Ali, Mohammad; Hering, Luisa M.; Meardon, Naomi; Austin, James; Brown, Rebecca L.; Skelly, Donal; Gillson, Natalie; Dobson, Susan L; Cross, Andrew; Sandhar, Gurjinder; Kilby, J A; Tyerman, Jessica K.; Nicols, Alexander R.; Spegarova, Jarmila Stremenova; Mehta, Hema; Hornsby, Hailey; Whitham, Ruth H.; Conlon, Christopher P.; Jeffery, Katie; Goulder, Philip; Frater, John; Dold, Christina; Pace, Matthew; Ogbe, Ane; Brown, Helen; Ansari, M Azim; Adland, Emily; Brown, Anthony; Chand, Meera; Shields, Adrian; Matthews, Philippa C.; Hopkins, Susan; Hall, Victoria; James, William; Rowland‐Jones, Sarah; Klenerman, Paul; Dunachie, Susanna; Richter, Alex; Duncan, Christopher J A; Barnes, Eleanor; Carroll, Miles W.; Turtle, Lance; Silva, T I de; Watson, Adam; Alhussni, Ahmed; Deeks, Alexandra; Webb-Bridges, Alice; Jämsén, Anni; Chawla, Akshita; Duncan, Christopher; O’Donnell, Denise; Weeks, Esme; Abuelgasim, Hibatullah; Xiao, He; Holmes, Jennifer; Haworth, Judy; Cutteridge, Joseph; Lillie, Katy; Romaniuk, Liana; Denly, Lucy; Kasanyinga, Mwila; Wilson, Robert L.; Thomas, Sarah; Gardiner, Siobhan; Tucker, Sean N.; Adlou, Syed; Silva, T de; Lawrie, Alison M.; Smith, Nick; Turton, H.; Zawia, Amira; Bayley, Mark; Fairman, Alexander S.; Harrington, Kimberly H.; Kirk, Richard; Marsh, Laura; Watson, Laura; Wood, Steven C.; Diffey, Brian; Jones, Cassandra; Lett, Lauren; Platt, G; Subramaniam, Krishanthi; Wootton, Daniel G.; Payne, Brendan A. I.; Hambleton, Sophie; Kelly, Sarah; Marston, J. H.; Poolan, S; Turner, David P. J.; Haniffa, Muzlifa; Stephenson, Emily; Adele, Sandra; Akhter, Hossain Delowar; Chinnakannan, Senthil; Lara, Catherine De; Donnison, Timothy; Hackstein, Carl-Philipp; Lee, L; Lim, Nicholas; Malone, Tom; Phillips, Eloise; Ramamurthy, N.; Robinson, Nicola; Sampson, Oliver; Eyre, David W; Simmons, Beatrice; Stafford, Lizzie; Mentzer, Alexander J.; Amini, Ali; Arancibia‐Cárcamo, Carolina V.; Provine, Nicholas M.; Travis, Simon; Dimitriadis, Stavros I.; Johnson, Síle A.; Foulkes, Sarah; Khawam, Jameel; Wellington, Edgar; Gilbert‐Jaramillo, Javier; Knight, Michael; Dupont, Maeva; Horner, Emily C.; Thaventhiran, James; Chalk, Jeremy

doi:10.1016/s2666-5247(21)00275-5

Cited by 145 publications

(155 citation statements)

References 29 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…It is also in agreement with a recent study of cellular and humoral responses to the first BNT162b2 vaccine dose in previously infected individuals who developed a stronger booster response when the interval between infection and vaccination was extended [ 4 ].…”

supporting

confidence: 91%

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply

2022

View full text Add to dashboard Cite

supporting

confidence: 91%

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply

2022

View full text Add to dashboard Cite

“…Another possibility is that one dose of vaccine could provide stronger protection for people previously infected. Angyal etal. (2022) reported that previously infected healthcare workers in the UK showed strong immune responses after only one dose, equivalent to those of people receiving two doses with no past history.…”

Section: Rationale Behind Delaying the Second Dosementioning

confidence: 99%

Vaccination strategies and transmission of COVID-19: Evidence across advanced countries

Kim

Lee

2022

Journal of Health Economics

View full text Add to dashboard Cite

Given limited supply of approved vaccines and constrained medical resources, design of a vaccination strategy to control a pandemic is an economic problem. We use time-series and panel methods with real-world country-level data to estimate effects on COVID-19 cases and deaths of two key elements of mass vaccination - time between doses and vaccine type. We find that new infections and deaths are both significantly negatively associated with the fraction of the population vaccinated with at least one dose. Conditional on first-dose coverage, an increased fraction with two doses appears to offer no further reductions in new cases and deaths. For vaccines from China, however, we find significant effects on both health outcomes only after two doses. Our results support a policy of extending the interval between first and second doses of vaccines developed in Europe and the US. As vaccination progresses, population mobility increases, which partially offsets the direct effects of vaccination. This suggests that non-pharmaceutical interventions remain important to contain transmission as vaccination is rolled out.

show abstract

“…B-depleting therapies increase the risk of severe COVID-19 [1] and have been shown to induce an impaired immune response to the SARS-COV2 vaccine [2]. There is a lack of data exploring the T-cell response to SARS COV2 vaccine [3,4], especially since it may be preserved in patients treated with rituximab [5].…”

mentioning

confidence: 99%

T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients

Heitz

Razanamahery

Audia

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Cited by 145 publications

References 29 publications

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply

Vaccination strategies and transmission of COVID-19: Evidence across advanced countries

T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients

Contact Info

Product

Resources

About